Developing enzyme therapy to treat Pseudoxanthoma elasticum
Enzyme Therapy for PXE: Breaking the Barrier of Ectopic Calcification
This study is exploring a new treatment for Pseudoxanthoma elasticum (PXE) by testing an enzyme that could help balance important minerals in the body, which may prevent harmful calcification, and it's aimed at people affected by this genetic condition.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Thomas Jefferson University NIH-funded |
| Lab location | 1 site (Philadelphia, United States) |
| Project ID | NIH-10689263 on NIH RePORTER |
What this research studies
This research focuses on Pseudoxanthoma elasticum (PXE), a genetic disorder that leads to harmful calcification in connective tissues. Using mouse models, the researchers aim to develop a new enzyme therapy that normalizes levels of inorganic pyrophosphate (PPi), which is crucial for preventing ectopic calcification. The study investigates the roles of specific proteins, ENPP1 and TNAP, in regulating PPi levels and tests a recombinant ENPP1 enzyme to see if it can effectively raise PPi levels in the body. If successful, this approach could lead to a novel treatment for PXE.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Pseudoxanthoma elasticum who experience symptoms related to ectopic calcification.
Not a fit: Patients without a diagnosis of Pseudoxanthoma elasticum or those with other unrelated conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a new therapeutic option for patients suffering from Pseudoxanthoma elasticum, potentially reducing morbidity and improving quality of life.
How similar studies have performed: While the approach of using enzyme therapy for PXE is innovative, similar strategies targeting ectopic calcification have shown promise in other conditions, indicating potential for success.
Where this research is happening
Philadelphia, United States
- Thomas Jefferson University — Philadelphia, United States (Active)
Researchers
- Principal investigator: Li, Qiaoli — Thomas Jefferson University
- Study coordinator: Li, Qiaoli
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.